Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration Cohorts

PURPOSE: The phase II CAPTIVATE study investigated first-line treatment with ibrutinib plus venetoclax for chronic lymphocytic leukemia in two cohorts: minimal residual disease (MRD)-guided randomized treatment discontinuation (MRD cohort) and fixed duration (FD cohort). We report tumor debulking an...

Descripción completa

Detalles Bibliográficos
Autores principales: Barr, Paul M., Tedeschi, Alessandra, Wierda, William G., Allan, John N., Ghia, Paolo, Vallisa, Daniele, Jacobs, Ryan, O'Brien, Susan, Grigg, Andrew P., Walker, Patricia, Zhou, Cathy, Ninomoto, Joi, Krigsfeld, Gabriel, Tam, Constantine S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Research Briefs: Clinical Trial Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561555/
https://www.ncbi.nlm.nih.gov/pubmed/35939599
http://dx.doi.org/10.1158/1078-0432.CCR-22-0504

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561555/
https://www.ncbi.nlm.nih.gov/pubmed/35939599
http://dx.doi.org/10.1158/1078-0432.CCR-22-0504

Ejemplares similares